Expression of galectin-3 and p-AKT in invasive ductal carcinoma of the breast and its clinical significance

Journal of Practical Oncology

Volumn 25, Issue 6, 2010, Pages 638-641

  Wang, Li Xia ^a   Chen, Li Rong ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Breast neoplasms pathology; Carcinoma, ductal, breast pathology; Galectins blood; Immunohistochemistry; Lymphnode metastasis; Prognosis

Indexed keywords

GALECTIN 3; PROTEIN KINASE B;

ARTICLE; BREAST CARCINOMA; CANCER STAGING; CANCER SURVIVAL; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; PROTEIN EXPRESSION;

EID: 78651296232     PISSN: 10011692     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Mathieu A, Saal I, Vuckovic A, et al. Nuclear Galectin-3 expression is an independent predictive factor of recurrence for adenocarcinoma and squamous cell carcinoma of the lung [J]. Mod Pathol,2005,18(9):1264-1271.
2. Yu LG, Andrews N, Zhao Q, et al. Galectin-3 interaction with thomsen-friedenreich disaccharide on cancer-associated MUCl causes increased cancer cell endothelial adhesion[J]. Biol Chem,2007,282(1):773-781.
3. Khaldoyanidi SK, Glinsky VV, Sikora L, et al. MDA-MB-435 human breast cancer carcinoma cell homo- and heterotypic adhesion under flow conditions is mediate in part by Thomsen-Friendenreich antigen-Galectin-3 interactions[J]. J Biol Chem,2003,278(6):4127-4134.
4. Honjo Y, Nangia-Makker P, Inohara H, et al. Down-regulation of Galectin-3 suppresses tumorigenicity of human breast carcinoma cells [J]. Clin Cancer Res, 2001,7(3):661-668. (Pubitemid 32707992)
5. Nangia-Makker P, Honjo Y, Sarvis R, et al. Galectin-3 induces endothelial cell morphogenesis and angiogenesis [J]. Am J Pathol,2000,156(3):899-905.
6. Chin YR, Toker A. Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer[J]. Cell Signalling,2009,21(4):470-476.
7. Zhou X, Tan M, Stone Hawthorne V, et al. Activation of the Akt/mammalian target of Rapamycin/4E-Bp1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers [J]. Clin Cancer Res,2004,10(20):6779-6788.
8. Tokunaga E, Oki E, Egashira A, et al. Deregulation of the Akt pathway in human cancer [J]. Curr Cancer Drug Targets,2008,8(4):27-36.
9. Carnero A, Blanco-Aparicio C, Renner O, et al. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications[J]. Curr Cancer Drug Targets,2008,8(4):187-198.
10. Clark AS, West K, Streicher S, et al. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells[J]. Mol Cancer Ther,2002,1(9):707-717.
11. Crowder RJ, Ellis MJ. Treating breast cancer through novel inhibitors of the phosphatidylinositol 3′-kinase pathway [J]. Breast Cancer Res,2005,7(5):212-214.
12. Tokunaga E, Kimura Y, Mashino K, et al. Activation of PI3K/AKT signaling and hormone resistance in breast cancer[J]. Breast Cancer,2006,13(2):137-144.
13. Oka N, Nakahara S, Takenska Y, et al. Galectin-3 inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by activating Akt in human bladder carcinoma cells[J]. Cancer Res,2005,65(17):7546-7553.
14. Lagana A, Gcetz JG, Cheung P, et al. Galectin binding to mgat5-modified N-glycans regulates fibronactin matrix remodeling in tumor cells[J]. Mol Cell Biol,2006,26(8):3181-3193.